

Attorney Docket No.: RTS-0258
Inventors: Bennett and Freier
Serial No.: 09/10,185
Filing Date: July 18, 2001
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (previously amended): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human glioma-associated oncogene-3 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding human glioma-associated oncogene-3 and inhibits the expression of human glioma-associated oncogene-3.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

B¹
Claim 3 (canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Attorney Docket No.: RTS-0258
Inventors: Bennett and Freier
Serial No.: 09/10,185
Filing Date: July 18, 2001
Page 3

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

B
Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 which is a chimeric oligonucleotide.

~~Claim 11~~ (canceled)

Attorney Docket No.: RTS-0258
Inventors: Bennett and Freier
Serial No.: 09/10,185
Filing Date: July 18, 2001
Page 4

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

B
Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (currently amended): A method of inhibiting the expression of glioma-associated oncogene-3 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of glioma-associated oncogene-3 is inhibited.

Claims 16-20 (canceled)